Effects of empagliflozin on serum uric acid level of patients with type 2 diabetes mellitus: a systematic review and meta‐analysis

Effects of empagliflozin on serum uric acid level of patients with type 2 diabetes mellitus: a systematic review and meta‐analysis

Abstract Background Serum uric acid levels are higher in patients with type 2 diabetes and prediabetes compared to healthy individuals, and hyperuricemia causes a significant rate of complications and mortality through heart and kidney diseases. Accordingly, the present systematic review and meta-an...

Full description

Bibliographic Details
Main Authors:	Yinyuan You, Yu Zhao, Mujuan Chen, Ying Pan, Zhenhui Luo
Format:	Article
Language:	English
Published:	BMC 2023-10-01
Series:	Diabetology & Metabolic Syndrome
Subjects:	Uric acid Urate Monosodium urate Empagliflozin Sodium–glucose transporter 2 inhibitors SGLT-2 inhibitors
Online Access:	https://doi.org/10.1186/s13098-023-01182-y

Similar Items

Empagliflozin Use and Fournier’s Gangrene: Case Report and Systematic Literature Review
by: Mario Antunes, et al.
Published: (2021-05-01)

Sodium–glucose co-transporter-2 inhibitors - empagliflozin and dapagliflozin as future therapy for Alport Syndrome, literature review
by: Magdalena Kłusek, et al.
Published: (2024-07-01)

Empagliflozin and the Prevention of Heart Failure
by: Douglas L. Mann, MD, et al.
Published: (2017-08-01)

Tubular Handling of Uric Acid and Factors Influencing Its Renal Excretion: A Short Review
by: Tubular Handling of Uric Acid and Factors Influencing Its Renal Excretion: A Short Review, et al.
Published: (2016-07-01)

Short-Term Treatment with Empagliflozin Resulted in Dehydration and Cardiac Arrest in an Elderly Patient with Specific Complications: A Case Report and Literature Review
by: Sopak Supakul, et al.
Published: (2022-06-01)

The Validation and Determination of Empagliflozin Concentration in the Presence of Grapefruit Juice Using HPLC for Pharmacokinetic Applications
by: Wael Abu Dayyih, et al.
Published: (2024-03-01)

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure
by: Nikole J. Byrne, BSc, et al.
Published: (2017-08-01)

Effect of Methylxanthines on Urate Crystallization: In Vitro Models of Gout and Renal Calculi
by: Jaume Dietrich, et al.
Published: (2024-08-01)

Clinical case of severe visceral complications with atypical localization in a patient with gout
by: G.P. Kuzmina, et al.
Published: (2023-03-01)

Sonographic estimation of monosodium urate burden predicts the fulfillment of the 2016 remission criteria for gout: a 12-month study
by: Edoardo Cipolletta, et al.
Published: (2021-07-01)

«URAT-INDEX» – NON-INVASIVE TOOL FOR PREDICTION OF URIC ACID CONTAINING STONES
by: N. K. Gadzhiev, et al.
Published: (2018-01-01)

Uric acid transporter inhibitors for gout
by: Philip K. Tan, et al.
Published: (2017-06-01)

A System for Discovering Novel Uricosurics Targeting Urate Transporter 1 Based on In Vitro and In Vivo Modeling
by: Xuechen Li, et al.
Published: (2024-01-01)

Empagliflozin: a potential anticancer drug
by: Wenwen Wu, et al.
Published: (2023-07-01)

Association between Empagliflozin Use and Electrocardiographic Changes
by: Daniel Antwi-Amoabeng, et al.
Published: (2022-07-01)

The Association of SGLT-2 inhibitors (Empagliflozin) with the development of hypernatremic dehydration: a case report
by: Diana Alegre-González, et al.
Published: (2025-10-01)

Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death
by: Zhaoyang Hu, et al.
Published: (2021-10-01)

Fucoidan from <i>Laminaria japonica</i> Inhibits Expression of GLUT9 and URAT1 via PI3K/Akt, JNK and NF-κB Pathways in Uric Acid-Exposed HK-2 Cells
by: Yu Zhang, et al.
Published: (2021-04-01)

Evaluation of the Effects of Empagliflozin on Serum Levels of Triglycerides and Cholesterol in Patients with Type 2 Diabetes Mellitus and Hypertriglyceridemia: A Prospective Study
by: Saeid Choobkar, et al.
Published: (2024-12-01)

Effects of empagliflozin on reproductive system in men without diabetes
by: Christophe Kosinski, et al.
Published: (2024-06-01)

Fournier’s gangrene in recent transplant recipient on empagliflozin
by: Lisa M. Raven, MBBS, FRACP, et al.
Published: (2024-05-01)

Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials
by: Toshinari Takahashi, et al.
Published: (2021-11-01)

Why Does Hyperuricemia Not Necessarily Induce Gout?
by: Wei-Zheng Zhang
Published: (2021-02-01)

Isolation and identification of uric acid-dependent Aciduricibacillus chroicocephali gen. nov., sp. nov. from seagull feces and implications for hyperuricemia treatment
by: Wenxuan Liu, et al.
Published: (2024-06-01)

Comparison of Extraglycemic effects of Dapagliflozin and Empagliflozin
by: Haroon Aziz, et al.
Published: (2023-06-01)

Empagliflozin: a wonder drug for the treatment of SIAD?
by: Ploutarchos Tzoulis
Published: (2024-10-01)

Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis
by: Zepeng Shi, et al.
Published: (2022-04-01)

Empagliflozin as a novel therapy for cirrhotic refractory ascites: a randomized controlled study
by: Mohamed Fathy Bakosh, et al.
Published: (2024-10-01)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects
by: Shen Z, et al.
Published: (2017-07-01)

Long-term effects of the SLC2A9 G844A and SLC22A12 C246T variants on serum uric acid concentrations in children
by: Hye Ah Lee, et al.
Published: (2018-09-01)

Population-specific factors associated with fractional excretion of uric acid
by: Ravi K. Narang, et al.
Published: (2019-11-01)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects
by: Hall J, et al.
Published: (2018-06-01)

Empagliflozin in type 1 diabetes
by: Mathieu C, et al.
Published: (2019-08-01)

Soft Coral-Derived Lemnalol Alleviates Monosodium Urate-Induced Gouty Arthritis in Rats by Inhibiting Leukocyte Infiltration and iNOS, COX-2 and c-Fos Protein Expression
by: Hsin-Pai Lee, et al.
Published: (2013-01-01)

Recent progress and perspectives on the relationship between hyperuricemia and periodontitis
by: Wenxue Hou, et al.
Published: (2022-11-01)

Understanding spinal gout: A comprehensive study of 88 cases and their clinical implications
by: Tommy Alfandy Nazwar, et al.
Published: (2024-05-01)

Tophaceous gout
by: Durga Neupane, et al.
Published: (2024-06-01)

Evaluation of Turmeric Nanoparticles as Anti-Gout Agent: Modernization of a Traditional Drug
by: Mubin Mustafa Kiyani, et al.
Published: (2019-01-01)

Downregulation of Transcription Factor T-Bet as a Protective Strategy in Monosodium Urate-Induced Gouty Inflammation
by: Qi-Bin Yang, et al.
Published: (2019-05-01)

Small intestinal tophus mimicking tumor
by: Pragya Katoch, et al.
Published: (2014-03-01)